SCHEMBL3383363

SCHEMBL3383363

NCCCN(CCCc1ccccc1)C(=O)O

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOA P21397 1/20 0.57
MC4R P32245 3/20 0.54
MC5R P33032 3/20 0.54
MC3R P41968 3/20 0.54
ALOX5 P09917 1/20 0.51
HTR2A P28223 1/20 0.50
ADRA2C P18825 1/20 0.50
AOC3 Q16853 1/20 0.50
HDAC3 O15379 1/20 0.48
MAPK1 P28482 1/20 0.48
ADRA1A P35348 1/20 0.48
HDAC4 P56524 1/20 0.48
SLC6A3 Q01959 1/20 0.48
HDAC1 Q13547 1/20 0.48
SMN1; SMN2 Q16637 1/20 0.48
HDAC7 Q8WUI4 1/20 0.48
HDAC2 Q92769 1/20 0.48
HDAC10 Q969S8 1/20 0.48
HDAC11 Q96DB2 1/20 0.48
HDAC8 Q9BY41 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3382221 0.95 MAOA (0.55) MAOAMC4RMC5RMC3RALOX5
SCHEMBL2584582 0.87 LIMK2 (0.56) MC4RMC5RMC3RADRA2C
SCHEMBL23120358 0.84 ALOX5 (0.53) ALOX5AOC3HDAC3MAPK1ADRA1A
SCHEMBL19438761 0.84 GAA (0.55) ALOX5AOC3HDAC3MAPK1ADRA1A
SCHEMBL26985651 0.82 ALOX5 (0.51) ALOX5HDAC3MAPK1ADRA1AHDAC4
SCHEMBL27075772 0.81 MC4R (0.61) MAOAMC4RMC5RMC3R
SCHEMBL3795459 0.81 MC4R (0.61) MAOAMC4RMC5RMC3R
SCHEMBL5933377 0.81 TDP1 (0.66) ALOX5AOC3HDAC3MAPK1ADRA1A
SCHEMBL19925599 0.80 LMNA (0.43) MC4RMC5RMC3RADRA2CHDAC3
SCHEMBL7857827 0.80 MC4R (0.51) MAOAMC4RMC5RMC3R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7727997-B2 N,N′-substituted-1,3-diamino-2-hydroxypropane derivatives ELAN PHARMACEUTICALS, INC. (US) 2010-06-01 US disclosed
US-20070213316-A1 Compounds that are effective inhibitors of beta-secretase; inhibitors of beta-secretase-mediated cleavage of amyloid precursor proteins; effective inhibitors of A beta production, and/or are effective to reduce amyloid beta deposits or plaques; treatment of disorders such as Alzheimer's Disease ELAN PHARMACEUTICALS, INC. 2007-09-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070213316-A1 Compounds that are effective inhibitors of beta-secretase; inhibitors of beta-secretase-mediated cleavage of amyloid precursor proteins; effective inhibitors of A beta production, and/or are effective to reduce amyloid beta deposits or plaques; treatment of disorders such as Alzheimer's Disease BACE1, BACE2, APP MAOA 809/4885MC4R 3845/4885MC5R 2615/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.